Belsomra vs Dayvigo: Titration Speed and Tolerability Compared

What Is the Core Difference Between Belsomra and Dayvigo?

Both suvorexant (Belsomra) and lemborexant (Dayvigo) are dual orexin receptor antagonists, meaning they quiet the brain's wakefulness-promoting orexin system rather than broadly sedating the central nervous system the way benzodiazepines do. The meaningful clinical difference is not the mechanism but the pharmacokinetics and the dose you actually take.

Suvorexant has a longer half-life (roughly 12 hours) compared with lemborexant (approximately 17 to 19 hours for lemborexant 5 mg and 10 to 12 hours for its active metabolites combined). Counterintuitively, Dayvigo's half-life is longer yet it tends to produce less next-morning sedation at its approved doses, likely because its receptor binding kinetics differ at lower plasma concentrations. Herring et al. (Lancet Neurology, 2014) established the phase 2/3 dose-ranging evidence that brought suvorexant to approval and first demonstrated this class's sleep-maintenance benefit without the full CNS suppression of older agents.

Sex-specific pharmacokinetics matter here. Women generally have lower body water and higher fat-to-lean mass ratios than men, which affects how lipophilic drugs like DORAs distribute and clear. Neither drug has a sex-stratified dosing label, but the FDA briefing documents for both noted higher peak plasma concentrations in women, which may partly explain why women report next-day grogginess more often than men in general hypnotic trials.

How Does Belsomra Titration Work?

Starting Dose and First-Week Experience

Belsomra is started at 10 mg taken no more than 30 minutes before bedtime, with at least 7 hours remaining before the planned wake time. The labeling allows an increase to 20 mg if the 10 mg dose is not effective enough, but it also explicitly permits a reduction to 5 mg if tolerability is a problem. The FDA prescribing information for suvorexant caps the dose at 20 mg and notes that doses above 20 mg were studied but not approved because adverse events, particularly next-day impairment, increased without proportional benefit.

Why Women Often Need the 5 mg Dose

Women in clinical practice frequently find that 10 mg already produces morning grogginess, particularly in the first one to two weeks before their bodies adjust. This is consistent with the higher Cmax data in women. If you are a smaller-framed woman, perimenopausal with altered sleep architecture, or taking a moderate CYP3A4 inhibitor (fluconazole, for example), starting at 5 mg off-label before moving to 10 mg is a reasonable clinical conversation to have with your prescriber, even though the label does not list 5 mg as a formal starting step.

Dose-Response Ceiling

The trial data from Herring et al. Showed that 40 mg and 80 mg suvorexant doses improved subjective total sleep time but produced unacceptable next-day impairment, driving the 20 mg ceiling 1. Staying at or below 20 mg matters especially for women who drive in the morning, operate machinery, or work early shifts.

How Does Dayvigo Titration Work?

Starting Dose

Dayvigo begins at 5 mg at bedtime, again with at least 7 hours before the planned wake time. After one week at 5 mg, if you still have trouble falling or staying asleep, the dose can be increased to 10 mg. That is the full titration sequence: two steps, one week apart. Compared with Belsomra's upward push toward 20 mg, the Dayvigo ceiling is 10 mg, which means you reach the top of the approved range quickly.

SUNRISE-1 and SUNRISE-2 Evidence

SUNRISE-1 (JAMA Network Open, 2019) was the phase 3 registration trial for lemborexant. It enrolled adults with insomnia disorder and compared lemborexant 5 mg, lemborexant 10 mg, placebo, and zolpidem extended-release 6.25 mg over one month. Lemborexant 10 mg improved subjective sleep onset latency by a mean of 22.1 minutes versus 0.6 minutes for placebo (p < 0.001), and lemborexant 5 mg showed similar sleep-maintenance benefit with fewer reports of somnolence the next day.

SUNRISE-2 was a 12-month safety and efficacy study that also included a head-to-head arm comparing lemborexant against zolpidem ER and adding longer-term tolerability data. Neither SUNRISE trial was designed as a direct head-to-head against suvorexant, so no trial has yet randomized women to both DORAs simultaneously. That is a real evidence gap, and any comparison between Belsomra and Dayvigo draws on cross-trial data, not a single randomized comparison.

Next-Day Alertness

Dayvigo 5 mg produced next-day driving performance (measured by standard deviation of lateral position, a validated road-tracking metric) comparable to placebo in a rigorous simulator study, while zolpidem ER 6.25 mg significantly impaired driving. This matters particularly for women who commute early or who care for children in the morning.

Tolerability: Which Drug Causes Fewer Side Effects?

Somnolence and Morning Grogginess

Next-day somnolence is the most reported side effect for both drugs. In the SUNRISE-1 trial, somnolence occurred in approximately 10% of participants on lemborexant 10 mg versus 1% on placebo 2. Suvorexant 20 mg in the Herring trial produced somnolence rates around 7 to 13% depending on the dose studied. Comparing those numbers across trials with different populations and designs is imprecise, but Dayvigo 5 mg consistently shows the lowest next-morning impairment of any approved DORA dose.

Sleep Paralysis and Hypnagogic Hallucinations

Both drugs carry a small risk of sleep paralysis and hypnagogic or hypnopompic hallucinations as class effects, because orexin suppression partially mimics the REM-sleep intrusion seen in narcolepsy. Rates in trials are low (under 2%), but if you have a history of sleep paralysis, discuss this with your provider before starting either drug.

Cataplexy-Like Events

Neither drug has produced cataplexy in published trials at approved doses, but the FDA label for both includes a warning to monitor for muscle weakness. Women with autoimmune conditions affecting muscle tone, such as myasthenia gravis, should avoid DORAs.

Complex Sleep Behaviors

The FDA added a boxed warning in 2019 covering all sedative-hypnotics, including both DORAs, regarding complex sleep behaviors: sleepwalking, sleep-driving, and other activities performed while not fully awake. Discontinue immediately if these occur. The rate is low but not negligible, and alcohol use sharply increases risk.

Women's Life-Stage Considerations

Insomnia affects women disproportionately across every reproductive transition. A WomanRx clinical framework for choosing between these drugs by life stage:

Reproductive Years (Ages 18 to 44)

If you are of reproductive age and sexually active without reliable contraception, read the pregnancy section below before starting either drug. Sleep disruption tied to the luteal phase (days 15 to 28 of the cycle) is common; progesterone's GABAergic activity may actually improve sleep in the follicular phase and worsen it when progesterone drops premenstrually. DORAs do not modulate GABA, so they may work more consistently across the cycle than benzodiazepine-class drugs, though no trial has stratified DORA outcomes by menstrual cycle phase. That is a direct evidence gap.

Trying to Conceive

Both Belsomra and Dayvigo should be stopped before attempting conception. Neither drug has human safety data adequate to reassure clinicians or patients. If insomnia is significantly affecting your health while you are trying to conceive, cognitive behavioral therapy for insomnia (CBT-I) is the first-line treatment with no fetal risk. ACOG recommends CBT-I as the preferred insomnia treatment during the reproductive years.

Pregnancy

Neither suvorexant nor lemborexant has adequate human pregnancy data. Animal reproduction studies for suvorexant showed increased fetal resorption at high doses. For lemborexant, developmental toxicity was observed in animals at doses that produced maternal exposures below those in humans at the 10 mg clinical dose. Both are considered Pregnancy Category not formally assigned post-2015, but their risk profiles place them in the "avoid unless benefit clearly outweighs risk" tier. If you discover you are pregnant while taking either drug, do not stop abruptly, but call your provider the same day to make a tapering plan.

Postpartum and Lactation

No published human lactation data exist for lemborexant. Limited animal data suggest suvorexant transfers into milk. Because both drugs cause sedation, transfer to a breastfed infant could impair the infant's arousal, which carries risk for sudden infant death. The clinical consensus is to avoid both drugs while breastfeeding. If postpartum insomnia is severe, discuss short-term doxylamine (which has more lactation data) or a referral for CBT-I with your provider. LactMed, the NIH lactation database, lists both drugs as insufficiently studied and recommends against use during lactation.

Perimenopause (Ages 40 to 55, Typically)

This is where DORAs see some of their highest real-world use in women, and for good reason. Sleep-maintenance insomnia is one of the most common and most undertreated symptoms of perimenopause, affecting up to 60% of perimenopausal women by some estimates. Hot flashes fragment sleep by triggering arousal from slow-wave and REM sleep, but orexin antagonism does not treat the hot flash itself. A DORA may help you return to sleep after a hot flash wakes you, but it will not reduce the number of hot flashes per night.

For women with both vasomotor symptoms and insomnia, combining a DORA with menopausal hormone therapy (MHT) or fezolinetant (Veozah) addresses both pathways. Fezolinetant is a neurokinin 3 receptor antagonist that reduces hot flash frequency at the hypothalamic level and has been shown to improve sleep quality as a secondary endpoint in the SKYLIGHT 1 and 2 trials. Ask your clinician whether combination therapy is appropriate for your symptom burden.

CYP3A4 drug interactions become more common in perimenopause as women are more often prescribed antifungals, some blood pressure medications, and antidepressants. Both DORAs are CYP3A4 substrates; strong CYP3A4 inhibitors (fluconazole, ketoconazole) can double plasma exposure and should prompt a dose reduction or drug switch.

Post-Menopause

Insomnia often persists after menopause even after vasomotor symptoms resolve, because menopause permanently alters sleep architecture, reducing slow-wave sleep. DORAs work independently of estrogen status, so they remain effective post-menopausally. Dayvigo 5 mg is often the preferred starting point in older postmenopausal women because the lower dose reduces the risk of falls, which is a significant concern in women over 65. The American Geriatrics Society Beers Criteria cautions against benzodiazepines and non-benzodiazepine hypnotics (Z-drugs) in older adults; DORAs, while not explicitly exempted, have a more favorable fall-risk profile in the published geriatric literature.

PCOS and Metabolic Considerations

Women with polycystic ovary syndrome (PCOS) have higher rates of sleep-disordered breathing and insomnia than age-matched controls, partly driven by androgen excess and insulin resistance. If undiagnosed obstructive sleep apnea (OSA) is driving insomnia, starting a sedating drug can worsen OSA-related oxygen desaturation. Rule out OSA before prescribing DORAs in any woman with PCOS, obesity (BMI > 30), or significant snoring. This is not a contraindication, but it is a required clinical checkpoint.

Should You Switch from Belsomra to Dayvigo?

When Switching Makes Sense

Switching from suvorexant to lemborexant is clinically reasonable in the following situations:

• You are experiencing persistent next-morning grogginess at suvorexant 10 mg or higher and have already tried stepping down to 5 mg.
• You need a shorter titration process; Dayvigo reaches the top of its approved range in one step at one week.
• You have started a CYP3A4 inhibitor that substantially raises suvorexant levels and your prescriber prefers to switch rather than reduce further.
• You are older (post-menopause, particularly over 65) and your provider wants the lower absolute dose ceiling for fall-risk reduction.

How to Switch

No pharmacological washout is needed because neither drug accumulates to a degree requiring a gap. Stop suvorexant on the last night you take it, and begin lemborexant 5 mg the following bedtime. Monitor for the first three to five nights for any rebound insomnia, which can occur with any hypnotic switch. Rebound insomnia after DORAs is milder than after benzodiazepines, but it is real.

A direct quotation from the SUNRISE-1 investigators captures the clinical expectation well: "Lemborexant 5 and 10 mg were both efficacious for sleep onset and sleep maintenance, with lemborexant 5 mg demonstrating a favorable profile relative to next-day residual effects."

When Switching May Not Help

If your primary sleep problem is sleep-onset insomnia rather than sleep-maintenance insomnia, and suvorexant 10 mg is not working, a DORA switch is unlikely to solve the problem. CBT-I, or an evaluation for underlying anxiety disorder, is more likely to address onset-specific insomnia. Switching DORAs in this scenario treats the drug choice rather than the diagnosis.

Pregnancy and Lactation Safety (Required Section)

Pregnancy: Avoid both drugs during pregnancy.

Suvorexant: Animal data at supratherapeutic doses showed fetal resorption and reduced pup body weight. No adequate well-controlled human studies exist. The FDA labeling for suvorexant states that the drug should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Lemborexant: Animal embryo-fetal development studies showed skeletal and visceral malformations at doses producing plasma exposures below the human therapeutic range. The FDA prescribing information for lemborexant similarly states to avoid use unless clinically essential.

Lactation: Avoid both drugs while breastfeeding.

No published human milk transfer data exist for lemborexant. Suvorexant is lipophilic and likely transfers to breast milk based on animal data. Infant sedation and impaired arousal are the primary concerns. Use CBT-I or consult a lactation-trained provider for alternatives. NIH LactMed recommends against use of either drug during lactation.

Contraception: Women of reproductive age taking either drug should use effective contraception because adequate data to confirm fetal safety do not exist. If you are planning pregnancy within six months, talk with your prescriber about discontinuing and transitioning to CBT-I.

Who This Drug Comparison Is Right For and Not Right For

Good candidates for Dayvigo 5 mg as a first choice

• Women over 60 who need a low starting dose with a simple one-step titration
• Perimenopausal women with sleep-maintenance insomnia and known next-morning commitments (early work, caregiving)
• Women already on suvorexant who report persistent grogginess despite stepping down to 10 mg

Good candidates for Belsomra 10 mg as a first choice

• Women in their 30s and 40s with combined sleep-onset and sleep-maintenance insomnia who have no next-morning impairment concerns
• Those whose insurance formulary covers suvorexant at a lower tier than lemborexant (formulary position varies significantly and affects out-of-pocket cost more than most clinical differences)
• Women who have tried lemborexant 10 mg without adequate effect and whose clinician wants to try a slightly different receptor kinetics profile before moving to a different drug class

Not the right choice for either drug

• Pregnant women or those actively trying to conceive (use CBT-I)
• Breastfeeding women (use CBT-I or doxylamine after specialist consultation)
• Women with severe hepatic impairment (both drugs are hepatically metabolized; suvorexant is contraindicated in severe hepatic impairment)
• Women with untreated moderate-to-severe OSA
• Women who drink alcohol regularly in the evening (risk of complex sleep behaviors rises sharply)